Details of the Drug

General Information of Drug (ID: DMW9ZFS)

Drug Name

AIKO-150

Synonyms

6beta-Naltrexol; beta-Naltrexol; 6beta-Hydroxynaltrexone; 6alpha-Hydroxynaltrexone; 49625-89-0; 6alpha-Naltrexol; UNII-J0W963M37T; CHEMBL140278; J0W963M37T; naltrexol; Naltrexone-6-beta-ol; alpha-Naltrexol; 6beta-Naltrexone; 6alpha-Naltrexone; 6-alpha-naltrexol; N-Cyclopropylmethyl-7,8-dihydro-14-hydroxynorisomorphine; SCHEMBL679700; DTXSID80197942; JLVNEHKORQFVQJ-PYIJOLGTSA-N; ZINC6092289; BDBM50001709; NCGC00165851-01; FT-0672600; Opioid neutral antagonists (iv, pain), Aiko Biotechnology; 6-beta-naltrexol

Indication

Disease Entry	ICD 11	Status	REF
Opioid dependence	6C43.2Z	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

343.4

Logarithm of the Partition Coefficient (xlogp)

-0.4

Rotatable Bond Count (rotbonds)

2

Hydrogen Bond Donor Count (hbonddonor)

3

Hydrogen Bond Acceptor Count (hbondacc)

5

Chemical Identifiers

Formula: C20H25NO4
IUPAC Name: (4R,4aS,7R,7aR,12bS)-3-(cyclopropylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
Canonical SMILES: C1C[C@]2([C@H]3CC4=C5[C@@]2(CCN3CC6CC6)[C@H]([C@@H]1O)OC5=C(C=C4)O)O
InChI: InChI=1S/C20H25NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,14-15,18,22-24H,1-2,5-10H2/t14-,15-,18+,19+,20-/m1/s1
InChIKey: JLVNEHKORQFVQJ-PYIJOLGTSA-N

Cross-matching ID

PubChem CID: 5486554
CAS Number: 49625-89-0
TTD ID: D00HBR

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor delta (OPRD1)	TT27RFC	OPRD_HUMAN	Inhibitor	[2]
Opioid receptor kappa (OPRK1)	TTQW87Y	OPRK_HUMAN	Inhibitor	[2]
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Antagonist	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Opioid dependence

ICD Disease Classification

6C43.2Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor mu (MOP)	DTT	OPRM1	5.94E-01	-0.02	-0.17
Opioid receptor delta (OPRD1)	DTT	OPRD1	5.52E-01	0.03	0.23

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT00829777) Safety Study of Intravenous 6 Naltrexol (AIKO-150) in Opioid-Dependent Subjects. U.S. National Institutes of Health.
2	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
3	Clinical pipeline report, company report or official report of signaturerx.